HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD – MashupMD

Blood Cancers Today

Oncology / Hematology

Blood Cancers Today is a property that provides hematologists and oncologists with news, education, and information relevant to their patients and practices, with insight from experts in the field. As the online home of the publication, bloodcancerstoday.com is updated daily, with the most current information from around the specialty and multimedia content, including exclusive interviews with presenters at major medical meetings.

Articles

Mashup Score: 2

HMAs Are ‘Cornerstone’ in High-risk MDS Treatment Says Jamile Shammo, MD | Blood Cancers Today - 26 day(s) ago

HMAs such as decitabine and cedazuridine (Inqovi) have become the “cornerstone” of treating high-risk patients.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  🚨 Out now! 🚨 On this week's episode of “The HemOnc Pulse,” Jamile Shammo, MD, of @NorthwesternU, joins host @chadinabhan to discuss how to approach treatment for #MDS, including treating patients with ESAs or HMAs. 🎧 Listen here! https://t.co/7yYTJPa3us https://t.co/JqFuBjgodx

Mashup Score: 4

New Initiative Seeks to Jump-start Era of CMML Care | Blood Cancers Today - 29 day(s) ago

A collaborative effort between CMML researchers and The Leukemia & Lymphoma Society hopes to jump-start CMML research.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  #CMML has lingered in the penumbra of MDS, but a collaborative effort hopes to jump-start understanding of this rare disease. Check out our latest feature, with insight from Lee Greenberger, PhD, of @LLSusa; @md_padron of @MoffittNews; and more! 📖 https://t.co/kBO2K3jGB8 https://t.co/qMROsHshov

Mashup Score: 8

Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 1 month(s) ago

“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.

Source: bloodcancerstoday.com

Categories: General Medicine News, Partners & KOLs

Tweet Tweets with this article
- Blood_Cancers
  
  🚨 Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. 🎙️ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL 🎧 Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc